New vaccine can neutralize Covid-19 strains

The new vaccine is prepared by mRNA technology, promising to create a breakthrough revolution.

According to Medical News, experts at Mahidol University, Bangkok, Thailand, have created a new biological vaccine that enhances the ability to fight nCoV.

Experiments in mice have shown a superior response of VLIP compared to the original vaccine, S-2P.

Research by a team of experts in Thailand used laboratory mice and discovered the strong antibody-neutralizing potential of circular RNA (a polymer molecule with a coding role). The study has been published in bioRxiv and is pending review.

Hemp protein is the main biological feature of nCoV, used as a component of the new vaccine. This type of protein has the ability to create a good and very strong immune response.

SARS-CoV-2 has evolved with many different strains to disable vaccine mRNA. However, these researchers have created antibodies that can combine with the mRNA vaccine, thereby neutralizing the new strains.

The protein they created is VLIP, which improves thermal stability while maintaining the movements of the RBD receptor-binding domain. Experiments on mice have shown a superior response of VLIP compared to the original vaccine, S-2P. This helps induce a broader immune response.

The Covid-19 mRNA vaccine is created based on linear mRNA molecules. These molecules are inherently unstable, but thanks to the influence of the covalent structure, they become more stable. RNA cycling also protects these molecules from being broken down by enzymes and allows proteins to last longer.

The VFLIP-X mutant protein contains 6 amino acids that can be substituted and incorporated in a biocyclic platform. They then discovered that the VFLIP-X mutation could fight nCoV.

They also determined whether VFLIP-X is capable of producing antibodies against certain strains of Covid-19. The results show that VFLIP-X is active when exposed to Omicron (B.1.1.529) - which is the most common strain today.

This study demonstrated the potential of the biologic vaccine VFLIP-X in inducing antiviral antibodies within 7 weeks of booster dose administration. It also induces favorable cellular immune responses.

These results are very promising and are considered to open up new avenues for testing next-generation vaccines with higher efficiency.